ROCKWELL MEDICAL, INC. 8-K

What Happened
Rockwell Medical, Inc. announced (via an 8-K filed Jan 5, 2026) that it and DaVita, Inc. entered into a Second Amendment to their Amended and Restated Products Purchase Agreement. The Amendment, dated December 31, 2025 and effective December 23, 2025, extends the Agreement by one year to December 31, 2026 and includes a price increase for products sold during the Extension Term. The underlying Agreement was originally dated September 18, 2023 and was previously amended effective March 31, 2025.

Key Details

• Amendment date: December 31, 2025; effective date: December 23, 2025.
• Extension: Agreement term extended one year to December 31, 2026.
• Pricing: The Amendment provides for a price increase on products for the Extension Term (amount/percentage not disclosed in the filing).
• Original agreement: Amended and Restated Products Purchase Agreement dated September 18, 2023 (previously amended March 31, 2025).

Why It Matters
The Amendment preserves Rockwell’s commercial relationship with DaVita through the end of 2026, providing continued revenue visibility from product sales to that customer. The agreed price increase could improve revenue per unit or margins for the Extension Term, but the filing does not disclose financial details or expected dollar impact. Investors should note the contract extension and price change as material developments in Rockwell’s commercial arrangements, while awaiting any future disclosures that quantify the financial effect.